Advertisement

Document › Details
Medigene AG. (9/22/20). "Press Release: Strategic Measures including Restructuring with Extension of Cash Runway and Improved EBITDA". Planegg.
Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces today measures to reduce the cash burn and secure the Company's financing into Q3 2022.
Medigene has been proactively progressing its product development activities to further position itself as a key player in the development of novel immunotherapies. To address this mission, the Company has decided to concentrate all future preclinical research and development activities on developing functionally enhanced TCR-T cells as treatments for solid tumors (MDG10XX), the most significant commercial opportunities for Medigene's clearly differentiated technologies.
Contingent on results from the Phase I part of its ongoing MDG1011 Phase I/II clinical trial in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients, Medigene has decided to look for a partner for the Phase II part of this clinical trial. Furthermore, Medigene had so far expected the completion of dosing of the third dose cohort in the Phase I dose-escalation part of the MDG1011 trial by end of 2020. This timeline is now likely to be extended into Q1 2021 due to feasibility challenges associated with treating hematological cancer patients with very advanced and highly aggressive disease. Other clinical trials and existing collaborations continue as planned.
This new strategic approach will be implemented with cost-saving measures and a reduction of the number of employees by approx. 25% compared to the headcount published with the half-year results 2020. These measures will be enacted beginning immediately. In this context, the Company expects one-time expenses in the amount of approximately Eur1 m, which will be incurred in the fiscal years 2020 and 2021. The guidance for 2020 regarding total revenues remains unchanged at Eur7-9 m. The guidance for research and development expenses is reduced to the range of Eur22-26 m (previously Eur24-29 m). Consequently, the guidance for the anticipated EBITDA loss improves to the range of Eur17-24 m (previously EBITDA loss of Eur19-27 m). Based on this planning, the Company is financed into Q3 2022 (previously end of 2021).
Prof. Dolores J. Schendel, CEO/CSO of Medigene AG, comments: "In a year which has presented many challenges on a global scale, we are taking strategic actions to extend our cash runway, primarily by focusing all new pre-clinical product development activities on our competitively differentiated, enhanced TCR-T therapies for solid tumor indications. Unfortunately, these cost savings necessitate headcount reductions. I would personally like to thank the entire Medigene team and our partners for the great work. We continuously strive to position ourselves as a key player in the development of novel immunotherapies. Focusing the pre-clinical product development activities is, we believe, the best path forward to meet our mission at Medigene of developing breakthrough cancer therapies that fundamentally improve patients' lives."
--- end of press release ---
About Medigene
Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Record changed: 2020-10-01 |
Advertisement

More documents for Medigene (Group)
- [1] Medigene AG. (10/19/20). "Press Release: Medigene and Cytovant Enter into Service Agreement for DC Vaccine Manufacturing Process Development". Planegg-Martinsried....
- [2] Medigene AG. (3/26/20). "Press Release: Medigene Provides Results for Fiscal Year 2019 and Outlook". Martinsried....
- [3] Imcyse. (8/5/19). "Press Release: Imcyse Announces Changes in Management and Board, Appoints Thomas Taapken as Executive Chairman". Liège....
- [4] Medigene AG. (5/14/19). "Press Release: Medigene Reports Financial & Business Results for the First Three Months of 2019". Martinsried....
- [5] Medigene AG. (5/9/19). "Press Release: Bluebird Presents Preclinical Data of First TCR Candidate from Medigene Collaboration. Start Clinical Development 2020". Martinsried....
- [6] Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried....
- [7] Medigene AG. (5/2/19). "Press Release: Medigene Presented Data on Favorable Safety Pattern of PRAME-specific TCR on Neuronal Cells at 2019 ASGCT Meeting". Martinsried....
- [8] Medigene AG. (4/4/19). "Press Release: Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia". Martinsried & Hong Kong....
- [9] Medigene AG. (2/25/19). "Press Release: European Patent Covering TCR Library Suitable for the Development of Neoantigen-specific TCRs". Martinsried....
- [10] Medigene AG. (2/11/19). "Press Release: Medigene Appoints Axel-Sven Malkomes as CFO/CBDO". Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top